Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Current Assets: 2010-2025

Historic Current Assets for Arrowhead Pharmaceuticals (ARWR) over the last 15 years, with Sep 2025 value amounting to $950.6 million.

  • Arrowhead Pharmaceuticals' Current Assets rose 36.69% to $950.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $950.6 million, marking a year-over-year increase of 36.69%. This contributed to the annual value of $950.6 million for FY2025, which is 36.69% up from last year.
  • Per Arrowhead Pharmaceuticals' latest filing, its Current Assets stood at $950.6 million for Q3 2025, which was up 0.39% from $946.9 million recorded in Q2 2025.
  • Arrowhead Pharmaceuticals' Current Assets' 5-year high stood at $1.1 billion during Q1 2025, with a 5-year trough of $237.9 million in Q4 2023.
  • Its 3-year average for Current Assets is $635.4 million, with a median of $570.5 million in 2024.
  • In the last 5 years, Arrowhead Pharmaceuticals' Current Assets crashed by 58.63% in 2023 and then skyrocketed by 139.82% in 2024.
  • Over the past 5 years, Arrowhead Pharmaceuticals' Current Assets (Quarterly) stood at $338.3 million in 2021, then skyrocketed by 69.98% to $575.0 million in 2022, then plummeted by 58.63% to $237.9 million in 2023, then skyrocketed by 139.82% to $570.5 million in 2024, then soared by 36.69% to $950.6 million in 2025.
  • Its last three reported values are $950.6 million in Q3 2025, $946.9 million for Q2 2025, and $1.1 billion during Q1 2025.